Endotag-1
Locally Advanced Pancreatic Cancer
SynCore Biotechnology Co., Ltd.Phase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Locally Advanced Pancreatic Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 3 | BB |
Irinotecan RenJi Hospital | Phase 2/3 | BB |
Sorafenib HonorHealth Research Institute | Phase 2 | B |
Acetylsalicylic Acid Assistance Publique - Hôpitaux de Paris | Phase 3 | B |
Plavix Assistance Publique - Hôpitaux de Paris | Phase 3 | B |
View all 9 →
Same molecule, other indications
Endotag-1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →